Influence of CYP Gene Polymorphism on Sodium Valproate levels And Clinical Outcome in Pediatric Epilepsy:A Cohort Study

ABSTRACT: Introduction: One of the metabolic processes of sodium valproate (SV) metabolism is cytochrome P450 (CYP)-mediated oxidation. Polymorphisms in the genes encoding CYP enzymes can cause changes in SV concentration and clinical outcome. The study's goal of the study was to explore the pattern of CYP gene polymorphisms in pediatric epileptics in terms of sodium valproate concentration and clinical outcome. Methodology: Ninety-nine pediatric epileptics aged 2 to 18 years who were receiving Sodium Valproate monotherapy were included in this cohort study. PCR-RFLP was used to examine the genetic polymorphism patterns of CYP2C9 and CYP3A4. HPLC was used to estimate the serum valproate concentration at the trough level. SPSS 23 examined the relationship between SV concentration and CYP genotypes. A

ORGANISM(S): Homo sapiens (human)

SUBMITTER:  

PROVIDER: S-BSST865 | biostudies-other |

SECONDARY ACCESSION(S): S-EPMC6266652

REPOSITORIES: biostudies-other